Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Wolfe Research
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wolfe Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. A number of other equities research analysts have also recently weighed in on BPMC. Scotiabank cut shares of Blueprint Medicines from […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wolfe Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. A number of other equities research analysts have also recently weighed in on BPMC. Scotiabank cut shares of Blueprint Medicines from […]
